Novonesis (Novozymes) B

Novonesis analysts lift target prices—Jefferies, BørsHus and Deutsche Bank now forecast up to 490 kr, backing a bullish stance amid modest share gains.

Novonesis CEO outlines bold China expansion, AI‑driven innovation, and greener biosolutions strategy for sustainable growth.

Discover how Novonesis’s cutting‑edge biofertilizers boost crop yields, cut synthetic fertilizer use, and align with EU sustainability goals.

EU approves HiPhorius phytase for poultry and swine, boosting phosphorus use, cut feed costs, and giving Novonesis a market‑wide advantage.

Corporate earnings revisions show mostly upside, but a recent downgrade for Novonesis highlights how regulatory and competitive factors can shift biopharma forecasts and investor sentiment.

Novozymes Q3 2025 report: modest sales rise, margin pressure and rising R&D costs threaten growth, but strong cash flow and ESG compliance offer upside for investors.

Novozymes B navigates turbulent market waters with strategic leadership appointments, but faces challenges from a high valuation and broader market uncertainty.

Novozymes A/S, a leading biotechnology company, is navigating a challenging market environment, but remains optimistic about its prospects and has shown positive signs with recent developments and decreased short interest.

Novozymes A/S reports strong financial performance despite global market volatility, with shareholders approving a dividend of approximately EUR 0.56 per share and EUR 0.27 per share.

Novozymes B’s management is under pressure to provide transparency on the company’s financial situation, recent transactions, and future plans, as investors remain uncertain about the company’s growth prospects.